A policy shift at NIH is set to remove a key training pathway for clinical trialists by ending support for K awards tied to clinical trial required announcements. The analysis highlights that hundreds of active K23 awards are scheduled to expire by July 13, 2027, potentially forcing early-career clinician-scientists to find alternate funding routes before leading randomized trials. On the trial-execution side, a separate editorial-style review focuses on the hard tradeoffs around first-in-human study risk control, arguing that reforms aimed at speeding programs must preserve safety governance. Together, the reports underscore a dual constraint: building RCT capability while keeping early-stage development compliant and efficient.